{"downloaded": true, "htmlmade": false, "full": {"id": "30446741", "source": "MED", "pmid": "30446741", "pmcid": "PMC6760546", "fullTextIdList": {"fullTextId": "PMC6760546"}, "doi": "10.1038/s41409-018-0382-3", "title": "Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study.", "authorString": "Yang J, Jiang J, Cai Y, Li S, Wan L, Zhu J, Liu H, Shao S, Bai H, Wang C, Song X.", "authorList": {"author": [{"fullName": "Yang J", "firstName": "Jun", "lastName": "Yang", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China."}}}, {"fullName": "Jiang J", "firstName": "Jieling", "lastName": "Jiang", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China."}}}, {"fullName": "Cai Y", "firstName": "Yu", "lastName": "Cai", "initials": "Y", "authorId": {"@type": "ORCID", "#text": "0000-0001-8804-2616"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China."}}}, {"fullName": "Li S", "firstName": "Su", "lastName": "Li", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China."}}}, {"fullName": "Wan L", "firstName": "Liping", "lastName": "Wan", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China."}}}, {"fullName": "Zhu J", "firstName": "Jun", "lastName": "Zhu", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China."}}}, {"fullName": "Liu H", "firstName": "Huixia", "lastName": "Liu", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China."}}}, {"fullName": "Shao S", "firstName": "Shan", "lastName": "Shao", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China."}}}, {"fullName": "Bai H", "firstName": "Haitao", "lastName": "Bai", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China."}}}, {"fullName": "Wang C", "firstName": "Chun", "lastName": "Wang", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China."}}}, {"fullName": "Song X", "firstName": "Xianmin", "lastName": "Song", "initials": "X", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China. shongxm@sjtu.edu.cn."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0001-8804-2616"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "7", "volume": "54", "journalIssueId": "2834753", "dateOfPublication": "2019 Jul", "monthOfPublication": "7", "yearOfPublication": "2019", "printPublicationDate": "2019-07-01", "journal": {"title": "Bone marrow transplantation", "ISOAbbreviation": "Bone Marrow Transplant", "medlineAbbreviation": "Bone Marrow Transplant", "NLMid": "8702459", "ISSN": "0268-3369", "ESSN": "1476-5365"}}, "pubYear": "2019", "pageInfo": "1049-1057", "abstractText": "Nowadays, the most wildly used regimens for graft-versus-host disease (GvHD) prophylaxis in haplo-hematopoietic stem cell transplantation (Haplo-HSCT) are based on in vivo T-cell depletion (TCD) with anti-thymocyte globulin (ATG) or posttransplant cyclophosphamide (PTCy). To improve the efficiency of GvHD prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood (Haplo-PBSCT-Cord), a novel regimen, which is composed of low dose of ATG (5\u2009mg/kg) and low-dose PTCy (50\u2009mg/kg) for GvHD prophylaxis, was evaluated in a prospective phase II clinical trial (Clinicaltrials.org NCT03395860). Thirty-two patients diagnosed with hematological malignancies were enrolled in this trial. All patients received myeloablative conditioning regimens except for three patients. The cumulative incidences (CIs) of grades II-IV and III-IV acute GvHD were 19.4% (95% CI, 5.5-33.3%) and 6.9% (95% CI, 0-16.3%) by day 100, respectively. The 1-year probability of relapse, disease free survival (DFS) and overall survival (OS) was 25.1% (95% CI, 7.3-42.9%), 59% (95% CI, 33.3-84.7%) and 78.4% (95% CI, 63-93.8%), respectively. The CIs of CMV and EBV reactivation by day 180 were 37.5% (95% CI, 19.8-55.2%) and 40.6% (95% CI, 22.6-58.6%), respectively. The results suggested that low-dose ATG with low-dose PTCy as GvHD prophylaxis in Haplo-PBSCT-Cord had promising activity.", "affiliation": "Department of Hematology, Shanghai General Hospital (affiliated to Shanghai Jiao Tong University), No. 100 Haining Road, 200080, Shanghai, China.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "Y", "descriptorName": "Hematologic Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "Y", "descriptorName": "Graft vs Host Disease", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "PC", "qualifierName": "prevention & control", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Cyclophosphamide", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Antilymphocyte Serum", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "Y", "descriptorName": "Cord Blood Stem Cell Transplantation"}, {"majorTopic_YN": "Y", "descriptorName": "Peripheral Blood Stem Cell Transplantation"}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Prospective Studies"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "Y", "descriptorName": "Unrelated Donors"}, {"majorTopic_YN": "N", "descriptorName": "Allografts"}]}, "chemicalList": {"chemical": [{"name": "Antilymphocyte Serum", "registryNumber": "0"}, {"name": "Cyclophosphamide", "registryNumber": "8N3DW7272P"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1038/s41409-018-0382-3"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6760546"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6760546?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "4", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2020-07-28", "dateOfCreation": "2018-11-18", "firstIndexDate": "2018-11-17", "fullTextReceivedDate": "2020-07-11", "dateOfRevision": "2020-07-28", "electronicPublicationDate": "2018-11-16", "firstPublicationDate": "2018-11-16"}, "htmllinks": "https://europepmc.org/articles/PMC6760546", "abstract": "Nowadays, the most wildly used regimens for graft-versus-host disease (GvHD) prophylaxis in haplo-hematopoietic stem cell transplantation (Haplo-HSCT) are based on in vivo T-cell depletion (TCD) with anti-thymocyte globulin (ATG) or posttransplant cyclophosphamide (PTCy). To improve the efficiency of GvHD prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood (Haplo-PBSCT-Cord), a novel regimen, which is composed of low dose of ATG (5\u2009mg/kg) and low-dose PTCy (50\u2009mg/kg) for GvHD prophylaxis, was evaluated in a prospective phase II clinical trial (Clinicaltrials.org NCT03395860). Thirty-two patients diagnosed with hematological malignancies were enrolled in this trial. All patients received myeloablative conditioning regimens except for three patients. The cumulative incidences (CIs) of grades II-IV and III-IV acute GvHD were 19.4% (95% CI, 5.5-33.3%) and 6.9% (95% CI, 0-16.3%) by day 100, respectively. The 1-year probability of relapse, disease free survival (DFS) and overall survival (OS) was 25.1% (95% CI, 7.3-42.9%), 59% (95% CI, 33.3-84.7%) and 78.4% (95% CI, 63-93.8%), respectively. The CIs of CMV and EBV reactivation by day 180 were 37.5% (95% CI, 19.8-55.2%) and 40.6% (95% CI, 22.6-58.6%), respectively. The results suggested that low-dose ATG with low-dose PTCy as GvHD prophylaxis in Haplo-PBSCT-Cord had promising activity.", "pdflinks": "https://europepmc.org/articles/PMC6760546?pdf=render", "journaltitle": "Bone marrow transplantation", "authorinfo": ["Yang J", "Jiang J", "Cai Y", "Li S", "Wan L", "Zhu J", "Liu H", "Shao S", "Bai H", "Wang C", "Song X"], "title": "Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study."}